-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

CAR T Cell Therapy for Second-line (2L) LBCL

Sponsor: Bristol Myers Squibb
Program: Product Theaters
Hematology Disease Topics & Pathways:
Diseases, Lymphoid Malignancies
Saturday, December 7, 2024: 11:30 AM-12:30 PM
Room 2 (San Diego Convention Center)
Speaker:
Wendy Johnson, PharmD, Bristol Myers Squibb
Disclosures:
No relevant conflicts of interest to declare.

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only
See more of: Product Theaters
<< Previous Product Theater | Next Product Theater >>